Researchers in the UK have developed a new treatment approach for aniridia-related keratopathy (ARK), a rare genetic ocular disease, namely, a collagen scaffold that delivers limbal epithelial stem cells and stromal stem cells to the area affected by ARK. The treatment resulted in improved ocular surface scores and visual acuities.
AI model beats human graders at spotting glaucoma risk in UK population retinal photos, boosting accuracy and strengthening the case for scalable AI vision screening.
A maternal high-fat diet can negatively affect the retinal structure in mice.
Real-world insights into Artelac Complete, a preservative-free, multi-component tear substitute
In this Q&A from EDES 2026 in Milan, Piotr A. Woźniak, MD, PhD, discusses his real-world evidence study on a dry eye lubricating drop, including its effects on tear film stability.
An investigational treatment for vision loss associated with Bardet-Biedl syndrome is being tested in the first three patients treated.
Private practice fellowships sharpen cataract and refractive skills with high volume, new tech, and hands-on practice management mentorship.
Waste, cost and carbon are converging to reshape how cataract centres choose instruments.
Home OCT now gives us the next dimension: time.
In this Q&A, Vance Thompson, MD, clears up myths about dry eye and LASIK wearing off, and explains how better screening and technology are making the procedure more precise for younger patients.
Findings highlight the need for routine bilateral endothelial assessment in herpetic eye disease
Choosing the right IOL for patients seeking spectacle independence is increasingly complex as novel optical designs enter the field. This comparative case report explores how a proven diffractive trifocal IOL (AT LISA tri 839MP) performs against a novel spiral optic IOL and what the real-world trade-offs mean for patient selection.
Shortcomings of early 27-G vitrectomy systems drove the development of new technologies designed to match or surpass the performance of larger-gauge systems. The DORC TDC VELOCE represents the latest advancement - a next-generation high-speed cutter that reaches its full potential when combined with the DORC EVA NEXUS surgical system.
The phase 2 Early Vitrectomy and Intravitreal Antibiotics for Post-Operative Exogenous Endophthalmitis study showed that performing early vitrectomy for acute endophthalmitis can offer better and faster visual outcomes than the current treatment of prescribing antibiotics first.
Susvimo works in conjunction with the company’s port delivery platform, Contivue, which was specifically engineered for use with Susvimo.
Why AI-driven functional imaging could change how clinicians assess and treat retinal disease
PRIMA, the first brain-computer interface approved for form vision restoration (reading letters, numbers, words) in patients with geographic atrophy (GA) secondary to age-related macular degeneration, is commercially available in Europe.
David E. I. Pyott, CBE, MD(Hon), MBA, MA, discusses expanding subspecialty training and internationally recognized credentials in underserved regions.
A 10-year analysis finds latanoprost accounts for 40% of glaucoma prescriptions in New Zealand.
The long-term outcomes after primary scleral buckling procedures for rhegmatogenous retinal detachments showed high anatomic success, improved vision, and a good safety profile.
Antineoplastics were the most frequently implicated drug class in review
Real-world data support EndoArt as donor-independent option in high-risk patients
Andy Chang and Mikhail Boukhny of BVI Medical discuss the company's new Experience Hub in Sant Cugat, Spain, a hands-on training facility built to gather surgeon feedback ahead of the Virtuoso platform's European launch.
Biologic therapies linked to high remission rates over 2-year follow-up
Researchers identify microbial shifts tied to corneal disease history
Deeper anterior chamber depth and shorter disease course predicted better surgical outcomes
Ectoine eye drops boost tear stability and ease redness and tired eyes, along with burning, foreign body and dryness sensations, offering fast, irritation-free relief for patients with dry eye disease.
The US FDA approves Lumvoa for TED in active or chronic stages, showing rapid proptosis and diplopia improvements; safety monitoring includes hearing, hyperglycemia and infusion reactions.
Real-world data show dexamethasone intravitreal implant improves vision and thickness in RVO macular edema, with earlier anti-VEGF switching yielding better gains.
Charlie Zhang, MD, reflects on the rising incidence, diagnostic challenges and multidisciplinary management of immune checkpoint inhibitor–associated uveitis
